✦ LIBER ✦

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

✍ Scribed by Robert A. Wolff; Martin Fuchs; Maria Di Bartolomeo; Anwar M. Hossain; Clemens Stoffregen; Steven Nicol; Volker Heinemann

Book ID: 112067011
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 152 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26692

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab in Combination With Chemothe

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

✍ Ohtsu, A.; Shah, M. A.; Van Cutsem, E.; Rha, S. Y.; Sawaki, A.; Park, S. R.; Lim 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Axitinib or Bevacizumab Plus FOLFIRI or

Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study

✍ Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carl 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 292 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Walla 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 608 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Brufsky, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 99 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB